Zalicus Inc. (ZLCS) Advancing Clinical Development of Z944, Its Novel, Oral, T-Type Calcium Channel Blocker, for the Treatment of Pain
6/4/2013 10:19:57 AM
More...
|
Zalicus Inc. (ZLCS) to Present at the Jefferies and Co. 2013 Global Healthcare Conference
5/29/2013 7:53:09 AM
More...
|
Zalicus Inc. (ZLCS) Presents Data on Novel, Oral, N- and T-Type Calcium Channel Blockers for the Treatment of Pain
5/10/2013 11:27:30 AM
More...
|
Zalicus Inc. (ZLCS) Presents Data on Novel, Oral, N- and T-Type Calcium Channel Blockers for the Treatment of Pain
5/10/2013 7:58:23 AM
More...
|
Zalicus Inc. (ZLCS) Enters $25 Million Committed Funding Agreement
5/8/2013 6:52:34 AM
More...
|
Zalicus Inc. (ZLCS) Reports Financial Results for the First Quarter 2013
5/2/2013 8:18:46 AM
More...
|
Zalicus Inc. (ZLCS) Granted Key Formulation Patent for Z160
4/2/2013 9:51:07 AM
More...
|
Zalicus Inc. (ZLCS) Presents Data Demonstrating Advantages of State-Dependent Ion Channel Screening
3/19/2013 9:38:07 AM
More...
|
Zalicus Inc. (ZLCS) Reports Financial Results for the Fourth Quarter and Year End 2012
3/6/2013 6:22:44 AM
More...
|
Zalicus Inc. (ZLCS) Granted Composition-of-Matter Patent for Z944
2/20/2013 10:34:58 AM
More...
|
|